

ReWire is an advanced peptide protocol built around ARA-290 (cibinetide), a synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin. Unlike traditional pain management, ARA-290 activates your body's innate repair receptor to reduce chronic inflammation, support small nerve fiber regeneration, and improve microvascular function without stimulating red blood cell production. It is especially suited for patients dealing with neuropathic discomfort, stubborn inflammatory conditions, or post-injury nerve damage that hasn't responded to conventional approaches.
ReWire targets neuropathic pain, small fiber neuropathy, and chronic systemic inflammation that disrupts nerve signaling and tissue repair. It is designed for patients experiencing burning, tingling, or numbness in the extremities, slow wound healing, microvascular dysfunction, or inflammatory conditions that haven't improved with standard anti-inflammatory protocols.
ARA-290 selectively activates the innate repair receptor, a signaling complex that shifts your immune response from inflammation toward tissue repair. Pro-inflammatory cytokines decrease while nerve-protective pathways activate, supporting small fiber regeneration and improved microcirculation. Administered as a daily subcutaneous injection over a multi-week cycle. No red blood cell stimulation.
Every ReWire protocol at Better Med Spa starts with a clinical consultation to evaluate your history, labs, and inflammatory markers before prescribing. We source pharmaceutical-grade ARA-290 from licensed compounding pharmacies and build dosing plans around your specific biology. Located in Lincoln Park, Chicago, with telehealth available statewide for ongoing protocol management.


We're here to answer your questions and provide the best services for your needs. Schedule a consultation to learn how to reach your aesthetic goals.
Targeted nerve repair and inflammation control through the innate repair receptor. $420 per month at Better Med Spa.
ARA-290, also known as cibinetide, is a synthetic 11-amino acid peptide derived from the tissue-protective region of erythropoietin (EPO). EPO is best known for its role in red blood cell production, but researchers discovered that a specific structural domain of the molecule carries powerful anti-inflammatory and tissue-repair properties independent of erythropoiesis. ARA-290 was engineered to retain those protective benefits while eliminating the blood cell stimulation that makes traditional EPO risky for non-anemic patients. At Better Med Spa in Lincoln Park, Chicago, we offer ARA-290 as part of our clinician-guided peptide therapy menu under the protocol name ReWire.
The distinction matters clinically. Traditional EPO increases hematocrit (the percentage of red blood cells in your blood), which raises risks for hypertension and clotting. ARA-290 does not trigger that pathway. Instead, it selectively activates the innate repair receptor (IRR), a complex formed by the EPO receptor and the beta common receptor (CD131). The IRR is upregulated in tissues under stress, meaning it becomes more active precisely where the body needs repair. This targeted activation makes ARA-290 fundamentally different from broad-spectrum anti-inflammatories or standard pain medications that mask symptoms without addressing the underlying damage.
When ARA-290 binds to the innate repair receptor, it initiates a cascade of downstream effects that shift the local immune environment from damage mode to repair mode. Pro-inflammatory cytokines like TNF-alpha and IL-6 decrease. Immune cells adopt a healing profile rather than an attack profile. The result is less swelling, reduced pain signaling, and lower oxidative damage at the site of injury or chronic inflammation.
At the neuronal level, ARA-290 supports mitochondrial function within nerve cells and reduces oxidative stress that degrades axonal transport. When mitochondria function properly, proteins required for nerve rebuilding reach damaged sites efficiently. Over weeks of consistent dosing, this translates into clinically measurable improvements in nerve fiber density and sensory function. Phase II clinical trials in patients with sarcoidosis-related small fiber neuropathy demonstrated significant increases in corneal nerve fiber density (a reliable surrogate marker for systemic small fiber health) alongside meaningful reductions in neuropathic pain scores.
ARA-290 also improves microvascular function. Small blood vessels feeding peripheral nerves regain better perfusion, which supports the metabolic demands of nerve repair. For patients in Chicago dealing with neuropathic symptoms that have resisted gabapentin, pregabalin, or duloxetine, this mechanism offers a fundamentally different approach: rather than dulling pain signals, ReWire addresses the structural and inflammatory roots of nerve dysfunction.
ReWire is designed for patients experiencing conditions linked to small fiber damage, chronic inflammation, or impaired tissue repair. At Better Med Spa in Lincoln Park, we typically see strong candidates in these categories:
Neuropathic pain patients. Burning, tingling, or numbness in the hands and feet. Temperature sensitivity changes. Pain that doesn't respond well to conventional options. ARA-290 has the most robust clinical data in this space, particularly for neuropathy associated with sarcoidosis and type 2 diabetes.
Chronic inflammatory conditions. Patients with systemic inflammation that disrupts multiple body systems. ARA-290 recalibrates immune signaling toward repair without broadly suppressing immunity, which makes it attractive for patients who need targeted inflammation control rather than blanket immunosuppression.
Post-injury nerve recovery. Patients recovering from procedures, injuries, or conditions that have left residual nerve damage. ARA-290's ability to support nerve fiber regeneration and improve microcirculation can complement surgical recovery or physical therapy timelines.
Longevity-focused patients. Emerging preclinical research suggests ARA-290 may support cardiovascular and renal tissue protection, reduce age-associated declines in heart function, and modulate neuroinflammation relevant to neurodegenerative processes. These applications remain early-stage, but patients with a preventive mindset often include ReWire in a broader longevity stack alongside Cellular Longevity (Epithalon) and Better Vitality NAD+.
ARA-290 is investigational and not FDA-approved for any specific indication. It should not be considered a replacement for established treatments for serious neurological or autoimmune conditions. Patients with active hematologic disorders, those currently on erythropoietin therapy, or anyone with contraindications identified during consultation should discuss alternative approaches with their provider. At Better Med Spa, we do not prescribe peptides without a clinical evaluation first.
ReWire (ARA-290) is $420 per month at Better Med Spa. Each month includes your peptide supply (pharmaceutical-grade ARA-290 from a licensed compounding pharmacy), bacteriostatic water for reconstitution, and ongoing provider access for dosing guidance. . Most protocols run 4 weeks, with reassessment at the 4-week mark to evaluate symptom response and adjust future dosing if needed.
Unlike clinics that charge per vial without clinical oversight, every ReWire protocol at Better Med Spa includes a consultation to confirm candidacy and a structured dosing plan built around your specific presentation. Peptide therapy without clinical context is guesswork. We don't do guesswork.
Price: $420/month
Administration: Subcutaneous injection, once daily, self-administered at home
Loading dose: 2 mg daily for week 1
Maintenance dose: 4 mg daily from week 2 onward
Recommended duration: 8 to 12 weeks (minimum 4 weeks to assess response)
Includes: Clinical consultation, pharmaceutical-grade peptide, bacteriostatic water, injection supplies, provider access
Available via: In-person (Lincoln Park) or telehealth (Illinois statewide)
Patients often ask how ReWire fits alongside other peptide protocols. The short answer: ARA-290 occupies a unique lane. It is not a tissue-repair peptide like BPC-157, not a growth hormone secretagogue like CJC-1295, and not a mitochondrial agent like SS-31. Its mechanism of action (innate repair receptor activation) is distinct from every other peptide on our menu.
Primary action: Innate repair receptor activation
Best for: Neuropathic pain, small fiber neuropathy, chronic inflammation, nerve regeneration
Pairs well with: Wolverine (BPC-157 + TB-500), Core Spark (SS-31), Calm Within (KPV)
Primary action: Tissue repair, tendon and ligament healing, gut restoration
Best for: Musculoskeletal injuries, post-surgical recovery, gut health
Pairs well with: ReWire (ARA-290), KLOW, Build & Define (IGF-1 LR3)
Primary action: Mitochondrial membrane stabilization
Best for: Cellular energy, exercise recovery, aging-related fatigue
Pairs well with: ReWire (ARA-290), Better Vitality NAD+, Cellular Longevity (Epithalon)
Primary action: Anti-inflammatory tripeptide (alpha-MSH derivative)
Best for: Gut inflammation, skin inflammation (eczema, psoriasis), immune modulation
Pairs well with: ReWire (ARA-290), KLOW, VIP
The most common stacking pattern we see in Lincoln Park is ReWire + Wolverine for patients with both nerve damage and soft tissue injury, or ReWire + Core Spark for patients who want nerve repair plus mitochondrial optimization. Your provider will recommend the right combination during your consultation.